Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 342

1.

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.

Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Kienast J, Staib P, Grüneisen A, Kern W, Reichle A, Maschmeyer G, Aul C, Lengfelder E, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W.

J Clin Oncol. 2009 Jan 1;27(1):61-9. doi: 10.1200/JCO.2007.15.4245. Epub 2008 Dec 1.

PMID:
19047294
2.

Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.

Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, Fonatsch C, Haase D, Schoch C, Hossfeld D, Lengfelder E, Aul C, Heyll A, Maschmeyer G, Ludwig WD, Sauerland MC, Heinecke A.

Blood. 1999 Jun 15;93(12):4116-24.

3.

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.

Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A; German AML Cooperative Group.

J Clin Oncol. 2003 Dec 15;21(24):4496-504.

PMID:
14673036
4.

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

Fröhling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K; AML Study Group Ulm. Acute myeloid leukemia.

Blood. 2002 Dec 15;100(13):4372-80. Epub 2002 Aug 8.

5.

Remission induction therapy: the more intensive the better?

Büchner T, Hiddemann W, Berdel W, Wörmann B, Löffler H, Schoch C, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Andreesen R, Balleisen L, Haase D, Eimermacher H, Aul C, Rasche H, Uhlig J, Grüneisen A, Reis HE, Hartlapp J, Hirschmann WD, Weh HJ, Pielken HJ, Gassmann W, Sauerland MC, Heinecke A.

Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S41-4.

PMID:
11587366
6.

Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.

Scholl S, Theuer C, Scheble V, Kunert C, Heller A, Mügge LO, Fricke HJ, Höffken K, Wedding U.

Eur J Haematol. 2008 Mar;80(3):208-15.

PMID:
18081718
7.

A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.

Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R; Japan Adult Leukemia Study Group AML 97 Study.

Cancer. 2005 Dec 15;104(12):2726-34.

8.

A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial.

Röllig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhäuser M, Platzbecker U, Stuhlmann R, Schuler U, Soucek S, Kramer M, Mohr B, Oelschlaegel U, Stölzel F, von Bonin M, Wermke M, Wandt H, Ehninger G, Schaich M; Study Alliance Leukemia.

Blood. 2010 Aug 12;116(6):971-8. doi: 10.1182/blood-2010-01-267302. Epub 2010 May 4.

9.

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.

Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, Haferlach T, Hiddemann W, Falini B.

Blood. 2005 Dec 1;106(12):3733-9. Epub 2005 Aug 2.

10.

FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation.

Yoshimoto G, Nagafuji K, Miyamoto T, Kinukawa N, Takase K, Eto T, Kato K, Hayashi S, Kamimura T, Ohno Y, Taniguchi S, Harada M.

Bone Marrow Transplant. 2005 Dec;36(11):977-83.

PMID:
16184177
11.

Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.

Colovic N, Tosic N, Aveic S, Djuric M, Milic N, Bumbasirevic V, Colovic M, Pavlovic S.

Ann Hematol. 2007 Oct;86(10):741-7. Epub 2007 Jun 20.

PMID:
17579862
12.

Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.

Rao AV, Valk PJ, Metzeler KH, Acharya CR, Tuchman SA, Stevenson MM, Rizzieri DA, Delwel R, Buske C, Bohlander SK, Potti A, Löwenberg B.

J Clin Oncol. 2009 Nov 20;27(33):5580-6. doi: 10.1200/JCO.2009.22.2547. Epub 2009 Oct 26.

PMID:
19858393
13.

Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.

Koh Y, Park J, Ahn KS, Kim I, Bang SM, Lee JH, Yoon SS, Soon Lee D, Yiul Lee Y, Park S, Kim BK.

Ann Hematol. 2009 Nov;88(11):1089-97. doi: 10.1007/s00277-009-0733-7. Epub 2009 Mar 19.

PMID:
19296110
14.

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.

Kantarjian H, O'brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E.

Cancer. 2006 Mar 1;106(5):1090-8.

15.

Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.

Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Döhner H, Döhner K; German-Austrian AML Study Group.

Blood. 2009 May 7;113(19):4505-11. doi: 10.1182/blood-2008-10-183392. Epub 2009 Feb 12.

16.

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.

Gardin C, Chevret S, Pautas C, Turlure P, Raffoux E, Thomas X, Quesnel B, de Revel T, de Botton S, Gachard N, Renneville A, Boissel N, Preudhomme C, Terré C, Fenaux P, Bordessoule D, Celli-Lebras K, Castaigne S, Dombret H.

J Clin Oncol. 2013 Jan 20;31(3):321-7. doi: 10.1200/JCO.2011.40.3642. Epub 2012 Dec 17.

PMID:
23248249
17.

High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia.

Tang R, Hirsch P, Fava F, Lapusan S, Marzac C, Teyssandier I, Pardo J, Marie JP, Legrand O.

Blood. 2009 Oct 1;114(14):2993-3000. doi: 10.1182/blood-2009-05-223115. Epub 2009 Jul 30.

18.

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Döhner K, Schlenk RF, Habdank M, Scholl C, Rücker FG, Corbacioglu A, Bullinger L, Fröhling S, Döhner H.

Blood. 2005 Dec 1;106(12):3740-6. Epub 2005 Jul 28.

19.

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, Haferlach C, Haferlach T.

Blood. 2009 Sep 10;114(11):2220-31. doi: 10.1182/blood-2009-03-213389. Epub 2009 Jul 8.

20.

Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.

Breccia M, Frustaci AM, Cannella L, Stefanizzi C, Latagliata R, Cartoni C, Diverio D, Guarini A, Nanni M, Rago A, Cimino G, Alimena G.

Hematol Oncol. 2009 Sep;27(3):148-53. doi: 10.1002/hon.889.

PMID:
19274612

Supplemental Content

Support Center